Scholar Rock Holding (SRRK) Total Current Liabilities (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Total Current Liabilities of $59.6 million for Q1 2026, up 58.73% year-over-year from $37.6 million in Q1 2025, and up 7.62% quarter-over-quarter from $55.4 million in Q4 2025.
Scholar Rock Holding (SRRK) Total Current Liabilities (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Total Current Liabilities history runs 10 years deep, the most recent figure standing at $59.6 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 58.73% year-over-year to $59.6 million; the TTM figure through Mar 2026 stood at $59.6 million (up 58.73% YoY), while the FY2025 annual figure was $55.4 million, up 18.07% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $59.6 million, up from $55.4 million in the prior quarter.
- The five-year high for Total Current Liabilities was $62.0 million in Q3 2025, with the low at $24.3 million in Q2 2023.
- The 5-year median for Total Current Liabilities is $37.5 million (2024), against an average of $39.7 million.
- The sharpest annual moves came in 2022 and 2026: Total Current Liabilities sank 52.29% in 2022, then soared 58.73% in 2026.
- Scholar Rock Holding's Total Current Liabilities stood at $36.4 million in 2022, then dropped by 10.03% to $32.7 million in 2023, then surged by 43.36% to $46.9 million in 2024, then gained by 18.07% to $55.4 million in 2025, then gained by 7.62% to $59.6 million in 2026.
- Business Quant data shows SRRK's Total Current Liabilities at $59.6 million in Q1 2026, $55.4 million in Q4 2025, and $62.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | 72.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 72.24 Mn |
| Mar 31, 2026 | 59.64 Mn |
| Dec 31, 2025 | 55.42 Mn |
| Sep 30, 2025 | 61.97 Mn |
| Jun 30, 2025 | 50.44 Mn |
| Mar 31, 2025 | 37.57 Mn |
| Dec 31, 2024 | 46.94 Mn |
| Sep 30, 2024 | 39.37 Mn |
| Jun 30, 2024 | 32.99 Mn |
| Mar 31, 2024 | 37.51 Mn |
| Dec 31, 2023 | 32.74 Mn |
| Sep 30, 2023 | 26.73 Mn |
| Jun 30, 2023 | 24.27 Mn |
| Mar 31, 2023 | 26.21 Mn |
| Dec 31, 2022 | 36.39 Mn |
| Sep 30, 2022 | 33.74 Mn |
| Jun 30, 2022 | 40.16 Mn |
| Mar 31, 2022 | 33.37 Mn |
| Dec 31, 2021 | 64.30 Mn |
| Sep 30, 2021 | 64.60 Mn |